Federated Hermes Inc. Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Federated Hermes Inc. lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 315,718 shares of the medical equipment provider's stock after purchasing an additional 27,615 shares during the quarter. Federated Hermes Inc. owned 0.45% of Lantheus worth $28,244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after buying an additional 32,551 shares during the last quarter. Reinhart Partners LLC. raised its holdings in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Swedbank AB lifted its holdings in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Raymond James Financial Inc. bought a new position in Lantheus during the 4th quarter valued at about $36,183,000. Finally, Boston Partners boosted its holdings in Lantheus by 57.5% in the fourth quarter. Boston Partners now owns 400,797 shares of the medical equipment provider's stock worth $36,201,000 after purchasing an additional 146,268 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of research reports. B. Riley decreased their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. Finally, Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Insiders Place Their Bets

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 in the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Trading Down 0.5 %

Shares of LNTH traded down $0.48 during trading hours on Monday, reaching $101.52. 169,772 shares of the stock traded hands, compared to its average volume of 953,159. Lantheus Holdings, Inc. has a 52-week low of $59.56 and a 52-week high of $126.89. The company has a market cap of $6.95 billion, a P/E ratio of 16.89 and a beta of 0.20. The company's 50-day moving average price is $94.00 and its two-hundred day moving average price is $95.56.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.